Enjofil 50 mg (Tablet)

Unit Price: ৳ 30.00 (1 x 4: ৳ 120.00)

Strip Price: ৳ 120.00

Medicine Details

Selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5)
Produces increased levels of cGMP in the corpus cavernosum
Results in smooth muscle relaxation and inflow of blood into the penile tissues
Has no effect in the absence of sexual stimulation

Causes local release of nitric oxide during sexual stimulation
Inhibition of PDE5 by Enjofil produces increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood
Rapidly absorbed after oral administration

Metabolized predominantly by hepatic metabolism (cytochrome P450 3A4)
Converted to an active metabolite with properties similar to the parent
Terminal half lives of about 4 hours
Maximum observed plasma concentrations reached within 30 to 120 minutes of oral dosing in the fasted state
Rate of absorption reduced when taken with a high fat meal
Cleared by hepatic microsomal isoenzymes
Excreted as metabolites predominantly in the feces and to a lesser extent in the urine

Recommended dose for erectile dysfunction: 50 mg taken approximately 1 hour before sexual activity
Dose may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg based on effectiveness and toleration
Maximum recommended dosing frequency is once per day
Recommended dose for pulmonary arterial hypertension: 20 mg three times a day
Should be taken approximately 4-6 hours apart, with or without food

Metabolism mediated by cytochrome P450 (CYP) isoforms 3A4 and 2C9
Inhibitors of CYP3A4 and CYP2C9 isoenzymes may reduce Enjofil clearance
Inducers of CYP3A4 and CYP2C9 isoenzymes may increase Enjofil clearance
Strong CYP3A4 inhibitors expected to have greater effects on Enjofil
Concomitant use with nitrates or nitric oxide donors is contraindicated
No effect on ritonavir pharmacokinetics
No effect on CYP2C9 inhibitors, CYP2D6 inhibitors, thiazide and related diuretics, ACE inhibitors, and calcium channel blockers

Various body system reactions including cardiovascular, digestive, hemic and lymphatic, metabolic and nutritional, musculoskeletal, nervous, respiratory, skin and appendages, special senses, and urogenital reactions
Serious cardiovascular, cerebrovascular, and vascular events reported post-marketing

Caution advised when PDE5 inhibitors are co-administered with alpha-blockers
Considerations for patients on alpha-blocker therapy
Potential for cardiac risk of sexual activity in patients with preexisting cardiovascular disease
Patients with underlying conditions sensitive to vasodilators should use with caution
No controlled clinical data on the safety or efficacy in certain patient groups
Prolonged erection and priapism have been reported infrequently
Caution in patients taking ritonavir
Potential for adverse events in patients with high systemic levels

In studies with healthy volunteers, adverse events were similar to those seen at lower doses but incidence rates and severities were increased
Standard supportive measures should be adopted as required
Renal dialysis not expected to accelerate clearance